Literature DB >> 34420180

Sinonasal SMARCB1 (INI1) Deficient Carcinoma with Yolk Sac Tumor Differentiation: A Case Report and Treatment Options.

Burak Hazir1,2, Berkay Şímșek3, Arzu Erdemír3, Fatih Gürler4, Ozan Yazici4, Yusuf Kizil5, Utku Aydíl5.   

Abstract

SMARCB1 (INI1) deficient carcinoma (SDC) is a newly-described, aggressive, high-grade malignancy of the adult population. Rarely, these tumors demonstrate yolk sac differentiation. Treatment protocols are not defined due to the rarity of this entity. A 55 year-old-male presented with a tumor originating in the maxillary sinus. He was treated with neoadjuvant therapy followed by radical surgery and adjuvant treatment. We review the literature and discuss the course of disease and treatments of sinonasal SDC with yolk sac tumor differentiation. To our knowledge, this is the sixth reported case of sinonasal SDC with yolk sac tumor differentiation. This is the first publication describing the clinical course and efficacy of therapeutic interventions.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  INI-1 deficient; Paranasal sinus malignancies; SMARCB1; Sinonasal malignancies; Yolk sac tumor

Mesh：

Substances：

Year:  2021        PMID： 34420180      PMCID： PMC9187833          DOI： 10.1007/s12105-021-01375-9

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN： 1936-055X


  13 in total

1.  SMARCB1 (INI-1)-Deficient Adenocarcinoma of the Sinonasal Tract: A Potentially Under-Recognized form of Sinonasal Adenocarcinoma with Occasional Yolk Sac Tumor-Like Features.

Authors:  Akeesha A Shah; Deepali Jain; Emad Ababneh; Abbas Agaimy; Aaron P Hoschar; Christopher C Griffith; Kelly R Magliocca; Bruce M Wenig; Lisa M Rooper; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2019-08-29

2.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Nasal Cavity, Paranasal Sinuses and Skull Base.

Authors:  Edward B Stelow; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2017-02-28

3.  SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.

Authors:  Abbas Agaimy; Arndt Hartmann; Cristina R Antonescu; Simion I Chiosea; Samir K El-Mofty; Helene Geddert; Heinrich Iro; James S Lewis; Bruno Märkl; Stacey E Mills; Marc-Oliver Riener; Thomas Robertson; Ann Sandison; Sabine Semrau; Roderick H W Simpson; Edward Stelow; William H Westra; Justin A Bishop
Journal:  Am J Surg Pathol       Date:  2017-04       Impact factor: 6.394

4.  SMARCB1 (INI1)-deficient sinonasal carcinoma: a series of 13 cases with assessment of histologic patterns.

Authors:  Aanchal Kakkar; Vijay Mariadas Antony; Raja Pramanik; Pirabu Sakthivel; Chirom Amit Singh; Deepali Jain
Journal:  Hum Pathol       Date:  2018-08-16       Impact factor: 3.466

5.  SMARCB1 (Integrase Interactor 1)-Deficient Sinonasal Carcinoma of the Maxillary Sinus: A Newly Described Sinonasal Neoplasm.

Authors:  Rabie M Shanti; Ariel Farahi; Joseph M Curry; Faizan Alawi
Journal:  J Oral Maxillofac Surg       Date:  2020-05-30       Impact factor: 1.895

6.  INI-1 (SMARCB1)-Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies.

Authors:  Khvaramze Shaverdashvili; Elham Azimi-Nekoo; Perry Cohen; Nadeem Akbar; Thomas J Ow; Balazs Halmos; Enrico Castellucci
Journal:  Oncologist       Date:  2020-06-12

Review 7.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

8.  SMARCB1-Deficient Sinonasal Carcinoma: A Case Report and Discussion of the Clinical Implications.

Authors:  Vanessa Trieu; Ricardo Mario Aulet; Allison Ciolino; Tamara Rimash
Journal:  Ann Otol Rhinol Laryngol       Date:  2019-03-15       Impact factor: 1.547

9.  SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms.

Authors:  Abbas Agaimy; Michael Koch; Michael Lell; Sabine Semrau; Wojciech Dudek; David L Wachter; Antje Knöll; Heinrich Iro; Florian Haller; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

10.  Case Report: SMARCB1 (INI-1)-Deficient Carcinoma of the Nasal Cavity with Pure Yolk Sac Tumor Differentiation and Elevated Serum AFP Levels.

Authors:  Chun-Yu Li; Ya-Mei Han; Ke Xu; Shu-Yue Wu; Xu-Yong Lin; Hong-Yi Cao
Journal:  Onco Targets Ther       Date:  2021-03-29       Impact factor: 4.147
View more
  2 in total

Review 1.  SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes.

Authors:  Victor Ho-Fun Lee; Raymond King-Yin Tsang; Anthony Wing Ip Lo; Sum-Yin Chan; Joseph Chun-Kit Chung; Chi-Chung Tong; To-Wai Leung; Dora Lai-Wan Kwong
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

2.  Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: SWI/SNF-deficient Sinonasal Neoplasms: An Overview.

Authors:  Abbas Agaimy
Journal:  Head Neck Pathol       Date:  2022-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.